Translational analyses of ATR inhibitor M1774 in a Phase I study in patients with solid tumors (DDRiver Solid Tumors 301)

被引：3
|
作者：
Tolcher, Anthony W.
Yap, Timothy A.
Plummer, Ruth
Grombacher, Thomas
Wang, Danyi
Schaffroth, Corinna
Hicking, Christine
Szucs, Zoltan
Locatelli, Giuseppe
de Bono, Johann S.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT271
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT271
引用
收藏
页数：3
相关论文
共 50 条
  • [21] PHASE I STUDY OF AMATUXIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Fujisaka, Y.
    Kurata, T.
    Tanaka, K.
    Kudo, T.
    Okamoto, K.
    Tsurutani, J.
    Kaneda, H.
    Kitamura, C.
    Namiki, M.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2013, 24
  • [22] Phase I study of docetaxel and topotecan in patients with solid tumors
    Tkaczuk, KH
    Zamboni, WC
    Tait, NS
    Meisenberg, BR
    Doyle, LA
    Edelman, MJ
    Hausner, PF
    Egorin, MJ
    Van Echo, DA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (06) : 442 - 448
  • [23] A phase I study of lapatinib and topotecan in patients with solid tumors
    Molina, J. R.
    Erlichman, C.
    Kaufmann, S.
    Adjei, A.
    Rubin, S.
    Friedman, R.
    Reid, J.
    Qin, R.
    Felten, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
    Yap, Timothy A.
    Krebs, Matthew G.
    Postel-Vinay, Sophie
    El-Khouiery, Anthony
    Soria, Jean-Charles
    Lopez, Juanita
    Berges, Alienor
    Cheung, S. Y. Amy
    Irurzun-Arana, Itziar
    Goldwin, Andrew
    Felicetti, Brunella
    Jones, Gemma N.
    Lau, Alan
    Frewer, Paul
    Pierce, Andrew J.
    Clack, Glen
    Stephens, Christine
    Smith, Simon A.
    Dean, Emma
    Hollingsworth, Simon J.
    CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5213 - 5224
  • [25] Phase I study of Elinafide in solid tumors
    Martin, M
    Casado, A
    Benavides, A
    Alonso, JL
    Garcia-Carbonero, I
    Sastre, J
    Moreno, E
    Diaz-Rubio, E
    ANNALS OF ONCOLOGY, 1998, 9 : 63 - 63
  • [26] Phase I study of lenalidomide in solid tumors
    Miller, Antonius A.
    Case, Doug
    Harmon, Michele
    Savage, Paul
    Lesser, Glenn
    Hurd, David
    Melin, Susan A.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (05) : 445 - 449
  • [27] A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
    Ueno, Hideki
    Kondo, Shunsuke
    Yoshikawa, Shusuke
    Inoue, Koichi
    Andre, Valerie
    Tajimi, Masaomi
    Murakami, Haruyasu
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 647 - 656
  • [28] A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
    Hideki Ueno
    Shunsuke Kondo
    Shusuke Yoshikawa
    Koichi Inoue
    Valérie Andre
    Masaomi Tajimi
    Haruyasu Murakami
    Investigational New Drugs, 2018, 36 : 647 - 656
  • [29] A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors
    Kristeleit, R.
    Calvert, H.
    Arkenau, H.
    Olmos, D.
    Adam, J.
    Plummer, E. R.
    Lock, V.
    Squires, M.
    Fazal, L.
    Judson, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] A phase I study of S-3304 a matrix metalloproteinase inhibitor in patients with solid tumors
    Creaven, PJ
    Sullivan, DM
    Eckhardt, G
    Bukowski, RM
    Bonomi, P
    Rao, S
    Ikeda, M
    Kambayashi, Y
    Y-Sawada, T
    Ohtani, M
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S77 - S77
12345